» Our current product base comprises a range of molecular imaging substances designed for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory disorders. These are currently undergoing regulatory approval as a precursor to our Phase I Human Trials.

» These substances have the brand name “PulmoBind”. We believe these products will quickly replace the incumbent technology for the Nuclear Medicine based diagnosis of Pulmonary Embolism, and further create new markets for the diagnosis of Pulmonary Hypertension and other disorders of the pulmonary circulatory system.